secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0001193125-23-069624
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar reports Q4 2022 net loss $9.4M; Phase 2 CTI-1601 trial on track with data 2H 2023
--------------------------------------------------------------------------------

- Net loss of $9.4M ($0.21 per share) in Q4 2022 vs $9.1M ($0.50 per share) in Q4 2021; FY 2022 net loss $35.4M.
- Cash, cash equivalents and marketable securities of $118.4M at Dec 31, 2022, projected runway into 2H 2024.
- Phase 2 trial first cohort (25 mg) of CTI-1601 fully enrolled; update on next steps expected Q2 2023 after FDA/IDMC review.
- Top-line safety, PK and PD (frataxin level) data from both cohorts expected in 2H 2023; Feb 2023 appointed Dr. Gopi Shankar as CDO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312523069624/0001193125-23-069624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312523069624/d475352d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-069624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer